Guanylate Cyclase (Guanylyl Cyclase)

An enzyme that catalyzes the conversion of GTP to 3',5'-cyclic GMP and pyrophosphate. It also acts on ITP and dGTP. (From Enzyme Nomenclature, 1992) EC 4.6.1.2.

Also Known As:

Guanylyl Cyclase; Deoxyguanylate Cyclase; Inosinate Cyclase; Cyclase, Deoxyguanylate; Cyclase, Guanyl; Cyclase, Guanylate; Cyclase, Guanylyl; Cyclase, Inosinate; Guanyl Cyclase; GTP pyrophosphate-lyase (cyclizing)

Networked: 692 relevant articles (18 outcomes, 53 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Dizhoor, Alexander M: 18 articles (10/2021 - 08/2007)
2.	Peshenko, Igor V: 17 articles (10/2021 - 08/2007)
3.	Olshevskaya, Elena V: 15 articles (10/2021 - 08/2007)
4.	Waldman, Scott A: 10 articles (10/2021 - 02/2009)
5.	Kurtz, Caroline B: 9 articles (10/2018 - 03/2010)
6.	Currie, Mark G: 9 articles (05/2018 - 03/2010)
7.	Hannig, Gerhard: 8 articles (01/2021 - 12/2010)
8.	Koch, Karl-Wilhelm: 8 articles (01/2019 - 01/2002)
9.	Potter, Lincoln R: 6 articles (01/2022 - 05/2007)
10.	Cohen, Mitchell B: 6 articles (12/2021 - 03/2011)

Related Diseases

1.	Constipation 12/01/2021 - "Guanylate cyclase-C (GC-C) agonists, which increase intestinal secretion and accelerate transit, are used to treat chronic constipation and constipation-predominant irritable bowel syndrome and are being evaluated for pediatric use. " 03/01/2011 - "Also considered is the potential for therapeutic manipulation of intestinal guanylate cyclase/cGMP signaling for the correction of chronic constipation and gastrointestinal cancer. " 01/01/2018 - "Here we test the hypothesis that linaclotide, a guanylate cyclase-C (GC-C) agonist approved for the treatment of IBS with constipation (IBS-C), may represent a novel therapeutic for BPS acting through a mechanism involving an inhibition of visceral organ cross-sensitization. " 12/01/2011 - "Linaclotide is a guanylate cyclase-C agonist currently being studied in Phase 3 trials for the treatment of IBS with constipation. " 01/01/2021 - "We recommend the use of chloride channel activators and guanylate cyclase activators to treat global IBS with constipation symptoms. "
2.	Hypoxia (Hypoxemia) 11/01/1996 - "Hypoxia also induced brain NOS in bronchial epithelium and inducible NOS in vascular smooth muscle but did not affect inducible NOS expression in macrophages or basal guanylyl cyclase activity in the lung. " 08/01/1990 - "Together, these in vitro results demonstrate that vascular cytosolic guanylate cyclase participates in an endothelium-dependent manner in the direct effects of hypoxia on cerebral arteries, and that the nature of this participation varies significantly between arteries. " 12/01/2011 - "In this study, we used in vitro and in vivo models to evaluate the therapeutic potential of 3-(5'-hydroxymethyl-2'-furyl)-1-benzylindazole (YC-1), a dual functioning chemical, as a direct activator of guanylyl cyclase and an inhibitor of hypoxia-inducible factor-1. " 12/31/2010 - "Redox regulation of guanylate cyclase and protein kinase G in vascular responses to hypoxia." 01/28/2009 - "In this work, after cardiomyocytes were incubated with 100, 200, 400, or 800 microM SF for 3 h, anoxia/reoxygenation injury was induced and intracellular Ca(2+) concentration, NO synthase (NOS) activity, guanylate cyclase activity, NO, and cGMP formation were measured appropriately. "
3.	Fibrosis (Cirrhosis) 01/01/2013 - "This study shows that Ang-(1-7) significantly inhibits intrahepatic vasoconstriction in response to key mediators of increased vascular and sinusoidal tone in cirrhosis via a receptor population present on the vascular endothelium that is sensitive to D-Pro(7)-Ang-(1-7) and causes activation of eNOS and guanylate cyclase-dependent NO signaling pathways." 04/03/2006 - "Hepatic guanylate cyclase activity is decreased in a model of cirrhosis: a quantitative cytochemistry study." 09/29/2022 - "Genetic Disruption of Guanylyl Cyclase/Natriuretic Peptide Receptor-A Triggers Differential Cardiac Fibrosis and Disorders in Male and Female Mutant Mice: Role of TGF-β1/SMAD Signaling Pathway." 01/01/2019 - "Combined Activation of Guanylate Cyclase and Cyclic AMP in Lung Fibroblasts as a Novel Therapeutic Concept for Lung Fibrosis." 12/01/2002 - "Activation of guanylate cyclase by NO was also altered in liver disease and was higher in lymphocytes from patients with cirrhosis or hepatitis than that in lymphocytes from controls. "
4.	Neoplasms (Cancer) 02/01/1978 - "In addition, guanylate cyclase activity was significantly greater in the tumor than normal prostate tissue and was decreased by the extract containing GCI. " 01/01/2018 - "The Guanylate Cyclase C-cGMP Signaling Axis Opposes Intestinal Epithelial Injury and Neoplasia." 05/01/2017 - "The receptor, guanylate cyclase C (GUCY2C), a tumor suppressor expressed by the intestinal epithelium, has emerged as a promising target. " 03/01/2011 - "In addition, accumulating evidence indicates that membrane-associated guanylate cyclase receptors regulate intestinal epithelial cell homeostatic proliferation and apoptosis as well as gastrointestinal malignancy. " 11/01/1999 - "To elucidate the mechanism underlying NO-induced p21 expression, we investigated the roles of tumor suppressor p53 and the guanylate cyclase-cGMP pathway. "
5.	Irritable Bowel Syndrome (Syndrome, Irritable Bowel) 12/01/2021 - "Guanylate cyclase-C (GC-C) agonists, which increase intestinal secretion and accelerate transit, are used to treat chronic constipation and constipation-predominant irritable bowel syndrome and are being evaluated for pediatric use. " 11/01/2022 - "The outstanding successes to date are the FDA approvals of two gut-restricted guanylate cyclase C-activating peptides to treat irritable bowel syndrome (constipated). " 03/01/2011 - "Ongoing clinical trials have found that guanylate cyclase activating peptides are safe and effective in the treatment of constipation-predominant irritable bowel syndrome and chronic constipation. " 01/01/2018 - "Linaclotide, a guanylate cyclase C agonist, has been shown in clinical trials to improve symptoms of irritable bowel syndrome with constipation (IBS-C). " 06/01/2022 - "Linaclotide is a guanylate cyclase-C (GCC) agonist that is found in intestinal epithelial cells and is used when treating chronic constipation (CC) and irritable bowel syndrome with constipation (IBS-C). "

Related Drugs and Biologics

1.	linaclotide
2.	Peptides (Polypeptides)
3.	Methylene Blue (Methylthioninium Chloride)
4.	Enterotoxin Receptors
5.	Secretagogues
6.	Nitric Oxide Synthase (NO Synthase)
7.	Acids
8.	Nitric Oxide (Nitrogen Monoxide)
9.	Atrial Natriuretic Factor (ANF)
10.	Natriuretic Peptides

Related Therapies and Procedures

1.	Therapeutics
2.	Resuscitation
3.	Artificial Respiration (Mechanical Ventilation)
4.	Drug Therapy (Chemotherapy)
5.	Traditional Medicine (Folk Remedies)